이뮤노포지㈜는 반감기 연장 플랫폼 기술 기반의 파이프라인을 보유한 신약개발 회사입니다.
Identification | Indication | Target | Discovery | Non-clinical | Phase I | Phase II | 비고 | |
---|---|---|---|---|---|---|---|---|
ELP Platform |
PF1801 | Polymyositis (PM)/ Dermatomyositis (DM) |
GLP-1R(Weekly) * Sarcopenia |
|
FDA ODD | |||
Duchenne Muscular Dystrophy (DMD) |
|
FDA ODD | ||||||
Inclusion Body Myositis (IBM) |
|
|||||||
Senile Sarcopenia |
|
|||||||
PF1804 | Cardiomyopathy(DMD), Heart Failure, Cystic Fibrosis |
VPAC2 |
|
FDA ODD | ||||
PF1805 | Achondroplasia | NPR-B |
|
|||||
PF1806 | Short Bowel Syndrome (SBS) | GLP-2R(Weekly) |
|
|||||
PF1807 | Sarcopenia | GLP-1R(Monthly) |
|
|||||
PF1809 | Long-acting hGH (~Monthly) |
|
||||||
PF1802 | Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease |
Undisclosed Bifunctional |
|
|||||
PF1803 | Osteoarthritis (OA) | Bifunctional OSCAR+ |
|
|||||
KF1601 | Drug Resistant Chronic Myeloid Leukemia (CML) |
BCR-ABL1 (T315I) |
|
FDA ODD |